4 unchanged sentences
Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
−Removed: Due to the inherent limitations of control
−Removed: systems, not all misstatements may be detected.
+Added: Due to the inherent limitations of control systems, not all misstatements may be detected.
These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake.
1 unchanged sentence
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022, the end of the period covered by this Annual Report on Form 10-K.
−Removed: Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.
+Added: Based upon such evaluation, our Chief Executive Officer and Chief
+Added: Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.
Management’s Annual Report on Internal Control Over Financial Reporting
35 unchanged sentences
(2) Financial Statement Schedules:
−Removed: All schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or notes thereto.
+Added: All schedules are omitted because they are either not required, not applicable, or the required information is shown in the consolidated financial statements or notes thereto.
(3) Exhibits.
60 unchanged sentences
and The Scripps Research Institute
−Removed: Phase I/IB Combination Study Agreement , dated October 5, 2015, by and between Corvus Pharmaceuticals, Inc.
−Removed: and Genentech, Inc.
−Removed: Amendment No.
−Removed: 1 to the Phase I/IB Combination Study Agreement , dated D ecember 20 , 2017, by and between Corvus Pharmaceuticals, Inc.
−Removed: and Genentech, Inc.
−Removed: Amendment No.
−Removed: 2 to the Phase I/IB Combination Study Agreement , dated August 1, 2019, by and between Corvus Pharmaceuticals, Inc.
−Removed: and Genentech, Inc.
−Removed: Phase 1b/II Combination Study Agreement dated May 1, 2017, by and between Corvus Pharmaceuticals, Inc.
−Removed: and Genentech, Inc.
−Removed: Amendment No.
−Removed: 1 to the Phase 1b/II Combination Study Agreement dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc.
−Removed: and Genentech, Inc.
Exclusive License Agreement dated April 21, 2017, by and between Corvus Pharmaceuticals, Inc.
and Monash University.
−Removed: Incorporated by Reference
−Removed: Exhibit Description
Framework Agreement, dated as of October 5, 2020, by and between Corvus Hong Kong Limited, Jiaxing Puissance Angel Equity Investment Partnership (Limited Partnership) and AP BIOTECH DEVELOPMENT CORP.
8 unchanged sentences
Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Incorporated by Reference
+Added: Exhibit Description
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 USC Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
48 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.